PAION AG is a Specialty Pharma Company headquartered in Aachen, Germany with sites in Cambridge, UK and New Jersey (USA). The company has a track record in developing hospital-based treatments for which there is substantial unmet medical need. PAION’s strategy is to extend its business model from a pure development company to a specialty pharmaceutical company with a focus on anaesthesia products. Remimazolam is intended to be the basis for its future marketing activities. PAION is listed at the Frankfurt Stock Exchange (Prime Standard Regulated Market, Stock Symbol PA8, ISIN DE-000A0B65S3).
www.paion.de